Business
aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution
Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present findings from its platform in an oral presentation and poster at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, which is scheduled to take place March 19 – 23 in Banff, Alberta, Canada. aTyr will present findings from its innovative tRNA synthetase platform that highlight ATYR0101, a potential therapeutic biologic based on a domain appended to Aspartyl-tRNA Synthetase (DARS) that is naturally occurring and selected through evolutionary intelligence to be released from cells to modulate extracellular signaling. ATYR0101 was found to bind to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of latent transforming growth factor beta binding protein 1 (LTBP1). LTBP1 is an extracellular matrix protein and key regulator of transforming growth factor beta (TGF-β), a central player in the pathogenesis of fibrotic diseases. These findings indicate that ATYR0101 may have therapeutic potential in fibrotic pathologies. Details of the oral and poster presentations appear below. The poster will be available on the aTyr website once presented. Title: Identification of latent transforming growth factor beta binding protein 1 (LTBP1) as a binding partner of aspartyl-tRNA Synthetase Authors: Tarsis F. Brust, Andrew Imfeld, Ying-Ting Wang, Yeeting Chong, Kristina Hamel, Alison Barber, Ann L. Menefee, Cory Soto, Gennyne Walker, Eileen Sun, Ryan A. Adams, and Leslie A. Nangle. aTyr Pharma, San Diego.Oral Presentation: Workshop 2: Fibrosis Research Funding and Partnering Academia/PharmaOral Presentation Date and Time: Tuesday, March 21, 2023, from 2:30PM – 4:30PM PTPoster Number: 1015Poster Session: Poster Session 1Poster Session Date and Time: Monday, March 20, 2023, from 7:30PM – 10:00PM PT “These findings provide further evidence establishing the extracellular functionality of ...